Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Surface Oncology, Inc.    SURF

SURFACE ONCOLOGY, INC.

(SURF)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
8.41(c) 9.33(c) 8.89(c) 8.83(c) 9.57(c) Last
852 883 3 494 767 936 532 582 790 924 823 Volume
-10.72% +10.94% -4.72% -0.67% +8.38% Change
More quotes
Financials (USD)
Sales 2020 38,6 M - -
Net income 2020 -25,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -13,1x
Yield 2020 -
Sales 2021 3,75 M - -
Net income 2021 -66,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,79x
Yield 2021 -
Capitalization 382 M 382 M -
Capi. / Sales 2020 9,90x
Capi. / Sales 2021 102x
Nbr of Employees 49
Free-Float 98,3%
More Financials
Company
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. 
More about the company
Notations Surperformance© of Surface Oncology, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SURFACE ONCOLOGY, INC.
09/16SURFACE ONCOLOGY : to Participate in the Oppenheimer Fall Healthcare Life Scienc..
AQ
09/16Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Scien..
GL
09/11SURFACE ONCOLOGY : to Participate in the H.C. Wainwright Global Healthcare Confe..
AQ
09/11Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conf..
GL
09/09SURFACE ONCOLOGY : to Present at the Baird Global Healthcare Conference
AQ
09/09Surface Oncology to Present at the Baird Global Healthcare Conference
GL
08/11Surface Oncology Reports Financial Results and Corporate Highlights for Secon..
GL
08/11SURFACE ONCOLOGY : Management's Discussion and Analysis of Financial Condition a..
AQ
08/11SURFACE ONCOLOGY, INC. : Results of Operations and Financial Condition, Financia..
AQ
08/05SURFACE ONCOLOGY : to Present at the 2020 Wedbush PacGrow Healthcare Virtual Con..
AQ
06/12SURFACE ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (fo..
AQ
05/28Surface Oncology Announces Change to Location and Format of 2020 Annual Meeti..
GL
05/22SURFACE ONCOLOGY, INC. : Entry into a Material Definitive Agreement, Termination..
AQ
05/21SURFACE ONCOLOGY : Continues Gains, Up 45%; In Clinical Trial Collaboration with..
DJ
05/20Surface Oncology Shares Rise on Merck Collaboration
DJ
More news
News in other languages on SURFACE ONCOLOGY, INC.

- No features available -

More news
Chart SURFACE ONCOLOGY, INC.
Duration : Period :
Surface Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SURFACE ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 10,50 $
Last Close Price 9,57 $
Spread / Highest target 25,4%
Spread / Average Target 9,72%
Spread / Lowest Target -5,96%
EPS Revisions
Managers
NameTitle
J. Jeffrey Goater President, Chief Executive Officer & Director
Daniel S. Lynch Executive Chairman
Jessica Fees Treasurer, Chief Financial & Accounting officer
Vito J. Palombella Chief Scientific Officer
Robert W. Ross Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SURFACE ONCOLOGY, INC.409.04%352
GILEAD SCIENCES, INC.-6.45%76 063
REGENERON PHARMACEUTICALS54.42%60 584
VERTEX PHARMACEUTICALS-3.37%54 719
WUXI APPTEC CO., LTD.58.33%39 347
BEIGENE, LTD.80.38%27 531